Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

Insulin-like growth factor-binding proteins (IGF-BPs) control the distribution, function and activity of insulin-like growth factors (IGFs) in various cell tissues and body fluids. They prolong the half-life of IGFs. Insulin-like growth factor-binding protein-1 (IGF-BP1) has been shown to have a role in the development and advancement of cancers. It is downregulated in hepatocellular carcinoma.

General description

Insulin-like growth factor-binding proteins (IGF-BPs) form high affinity complexes with both insulin-like growth factor- I and II (IGF-I and IGF-II). Currently there are seven named IGF-BPs. Insulin-like growth factor-binding protein-1 (IGF-BP1) is a 25.4kDa cysteine-rich secreted protein. It is the most abundant IGF-BP in amniotic fluid and is expressed in liver, decidua and kidneys. Levels of IGF-BP1 in serum are lowest after food. It binds to both IGF-I and IGF-II with equal affinity. Phosphorylated IGF-BP1 hinders IGF actions, whereas non-phosphorylated IGF-BP1 is stimulatory. Recombinant human IGF-BP1 is a 25.4kDa protein consisting of 235 amino acid residues (Isoform A).

Physical form

Lyophilized from 10 mM Sodium Phosphate, pH 7.5.

Reconstitution

Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

Sequence

MAPWQCAPCS AEKLALCPPV SASCSEVTRS AGCGCCPMCA LPLGAACGVA TARCARGLSC RALPGEQQPL HALTRGQGAC VQESDASAPH AAEAGSPESP ESTEITEEEL LDNFHLMAPS EEDHSILWDA ISTYDGSKAL HVTNIKKWKE PCRIELYRVV ESLAKAQETS GEEISKFYLP NCNKNGFYHS RQCETSMDGE AGLCWCVYPW NGKRIPGSPE IRGDPNCQIY FNVQN